APP and Cognitive impairment: miR-181a negatively targets forkhead box protein O1 (FOXO1), decreasing amyloid plaque deposition in the hippocampus and cortex, mitigating pericyte loss and BBB disruption in APP/PS1 mice, and ameliorating cognitive impairment in mice [55].